LifeMD Inc (LFMD)
7.84
+0.22
(+2.89%)
USD |
NASDAQ |
May 24, 16:00
7.835
0.00 (0.00%)
After-Hours: 20:00
LifeMD Research and Development Expense (Quarterly): 2.087M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 2.087M |
| December 31, 2023 | 1.998M |
| September 30, 2023 | 1.498M |
| June 30, 2023 | 1.381M |
| March 31, 2023 | 1.184M |
| December 31, 2022 | 1.019M |
| September 30, 2022 | 0.8216M |
| June 30, 2022 | 0.7011M |
| March 31, 2022 | 0.4283M |
| December 31, 2021 | 0.3864M |
| September 30, 2021 | 0.1281M |
| Date | Value |
|---|---|
| June 30, 2021 | 0.1226M |
| March 31, 2021 | 0.3111M |
| December 31, 2020 | 0.1579M |
| September 30, 2020 | 0.1183M |
| June 30, 2020 | 0.0923M |
| March 31, 2020 | 0.0781M |
| December 31, 2019 | 0.0651M |
| September 30, 2019 | 0.0612M |
| June 30, 2019 | 0.0508M |
| March 31, 2019 | 0.0457M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.0508M
Minimum
Jun 2019
2.087M
Maximum
Mar 2024
0.6345M
Average
0.3487M
Median
Research and Development Expense (Quarterly) Benchmarks
| Veradigm Inc | 23.68M |
| TruBridge Inc | 10.69M |
| Streamline Health Solutions Inc | 1.394M |
| PetMed Express Inc | -- |
| LENZ Therapeutics Inc | 10.54M |